PTCT - PTC Therapeutics Inc
IEX Last Trade
35.27
-0.260 -0.737%
Share volume: 334,064
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$35.53
-0.26
-0.73%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-10-27 | 2023-02-21 | 2023-04-27 | 2023-08-03 | 2023-10-26 | 2024-02-29 | 2024-04-25 | |
| Assets | |||||||||
| Total Assets | 1.804 B | 1.576 B | 1.706 B | 1.609 B | 1.338 B | 1.260 B | 1.896 B | 1.790 B | |
| Current Assets | 694.676 M | 517.262 M | 693.785 M | 613.392 M | 589.691 M | 540.362 M | 1.219 B | 1.169 B | |
| Inventories | 15.004 M | 14.812 M | 21.808 M | 26.649 M | 32.018 M | 35.752 M | 30.577 M | 30.058 M | |
| Other Current Assets | 38.184 M | 89.562 M | 105.658 M | 98.573 M | 42.227 M | 44.082 M | 150.491 M | 56.207 M | |
| Short Term Investments | 38.184 M | 89.562 M | 105.658 M | 98.573 M | 42.227 M | 44.082 M | 150.491 M | 56.207 M | |
| Total Receivables | 135.943 M | 124.456 M | 155.614 M | 201.867 M | 177.503 M | 165.718 M | 160.822 M | 197.660 M | |
| Current Cash | 505.545 M | 288.432 M | 410.705 M | 286.303 M | 337.943 M | 294.810 M | 876.739 M | 884.813 M | |
| Total Non-current Assets | 1.109 B | 1.059 B | 1.012 B | 995.447 M | 748.433 M | 719.523 M | 677.069 M | 620.891 M | |
| Property Plant Equipment | 64.913 M | 66.889 M | 72.590 M | 79.492 M | 82.129 M | 85.031 M | 87.089 M | 92.779 M | |
| Other Assets | 60.338 M | 55.115 M | 48.582 M | 47.878 M | 35.648 M | 34.737 M | 36.246 M | 24.545 M | |
| Intangible Assets | 760.154 M | 749.890 M | 705.891 M | 686.205 M | 451.629 M | 423.342 M | 379.497 M | 330.040 M | |
| Goodwill | 82.341 M | 82.341 M | 82.341 M | 82.341 M | 82.341 M | 82.341 M | 82.341 M | 82.341 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.804 B | 1.576 B | 1.706 B | 1.609 B | 1.338 B | 1.260 B | 1.896 B | 1.790 B | |
| Total liabilities | 1.986 B | 1.803 B | 2.053 B | 2.066 B | 1.917 B | 1.931 B | 2.714 B | 2.684 B | |
| Total current liabilities | 567.371 M | 420.076 M | 406.236 M | 441.634 M | 476.342 M | 492.118 M | 603.100 M | 574.546 M | |
| Accounts Payable | 22.881 M | 20.862 M | 27.268 M | 26.311 M | 25.741 M | 19.152 M | 6.045 M | 27.459 M | |
| Other liabilities | 843.306 M | 842.568 M | 852.378 M | 832.218 M | 698.870 M | 696.610 M | 1.656 B | 1.648 B | |
| Current long term debt | 152.082 M | 2.583 M | 3.000 M | 1.857 M | 2.230 M | 2.611 M | 3.000 M | 1.948 M | |
| Long term debt | 301.135 M | 301.424 M | 590.397 M | 589.275 M | 589.827 M | 590.358 M | 301.397 M | 300.086 M | |
| Other liabilities | 843.306 M | 842.568 M | 852.378 M | 832.218 M | 698.870 M | 696.610 M | 1.656 B | 1.648 B | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -182.218 M | -226.904 M | -347.086 M | -457.561 M | -579.268 M | -670.810 M | -818.555 M | -893.916 M | |
| Common stock | 71.373 M | 71.655 M | 72.672 M | 73.729 M | 74.730 M | 75.378 M | 75.516 M | 76.496 M | |
| Retained earnings | -2.377 B | -2.486 B | -2.657 B | -2.796 B | -2.995 B | -3.128 B | -3.284 B | -3.375 B |